Not real patients

A CLEAR CHOICE

AKLIEF® (trifarotene) Cream, 0.005%, reduces acne while helping improve acne scars and dark marks left by acne.1,2,3ab

A clear choice for you

AKLIEF Cream is a prescription topical retinoid and the first FDA approved acne treatment containing trifarotene, a highly precise and powerful retinoid. AKLIEF Cream works to rapidly reduce acne lesions as early as one week and has been shown to help prevent and reduce marks left by acne, such as acne scarring and post-inflammatory hyperpigmentation (PIH).abcd It is safe and effective across all skin types and skin tones.

Why AKLIEF Cream?

Clinical studies show that AKLIEF Cream helps reduce active acne. It has also been studied for acne scars and dark marks that acne can leave behind.2,3cd Treating acne early may help lower the chance of lasting marks.

Visible Acne Improvement

Some people saw acne improve in as early as 2 weeks. AKLIEF Cream helps reduce pimples, blackheads, and whiteheads on the face and body.⁵

Acne Scar Prevention and Reduction

Treating acne early may help lower the chance of acne scars. In a clinical study, AKLIEF Cream helped reduce the number and severity of acne scars.2c

Rapid Reduction in Dark Marks

Dark marks can remain visible on the skin even after acne clears. Clinical studies have shown that AKLIEF Cream can help improve acne-related dark marks, with visible improvement seen over 3 months and continued improvement over time.3cd

Why It’s the Clear Choice

How to Use AKLIEF Cream

Adding AKLIEF Cream to your daily routine is simple. It is made for once-daily use and has a smooth cream feel. In a clinical study, 100% of patients said they were satisfied with how AKLIEF Cream felt on their skin.⁷ Learn how to apply AKLIEF Cream as directed and get tips for making it part of your daily skincare routine.

Clear Skin Starts Here
Not a real patient

Save on AKLIEF Cream

If your healthcare provider prescribed AKLIEF Cream, you may be able to save on your prescription. Eligible patients with commercial insurance may qualify. Review program details and eligibility information to learn how much you could save.

Activate Your Savings
About acne

a. Studied in acne patients from 9 to 58 years of age with diverse skin types and moderate-to-severe acne. Nodulocystic acne was excluded from the trials.

b. Significant improvement seen as early as Week 1 in the pivotal clinical trials.

c. Improvements in acne scarring were secondary to clearing acne. In the dark-mark study, the primary end point at Week 24 was absolute change from base line in total atrophic acne scar count. At Week 24, there was no statistically significant difference between AKLIEF Cream and the comparison cream for post-inflammatory hyperpigmentation (PIH). 

d. The primary endpoint was the overall disease severity score (ODS). No statistical significance between AKLIEF Cream and vehicle at Week 24 was seen.



References

  1. AKLIEF® (trifarotene) Cream, 0.005% [Prescribing Information]. Dallas, TX: Galderma Laboratories, L.P.

  2. Schleicher S, et al. Trifarotene reduces risk for atrophic acne scars: Results from a phase 4 controlled study. Dermatol Ther (Heidelb). 2023;13(12):3085–3096.
  3. Alexis A, et al. Efficacy and safety of trifarotene in acne-induced post-inflammatory hyperpigmentation. Int J Dermatol. 2024;63(6):806–815.
  4. Aubert J, et al. Trifarotene: Development of a potent and selective RAR-γ agonist for topical treatment of acne. Br J Dermatol. 2018;179(2):442–456.
  5. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–1699.
  6. Blume-Peytavi U, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166–173.
  7. Galderma. Data on file. Clinical Study 202394. Dallas, TX: Galderma Laboratories, L.P.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.